Preliminary evidence of disease response to the pan deacetylase inhibitor panobinostat (LBH589) in refractory Hodgkin Lymphoma

Michael Dickinson, David Ritchie, Daniel J. Deangelo, Andrew Spencer, Oliver G. Ottmann, Thomas Fischer, Kapil N. Bhalla, Angela Liu, Katie Parker, Jeffrey W. Scott, Mark Bishton, H. Miles Prince

Research output: Contribution to journalArticle

83 Scopus citations

Abstract

There are few treatment options for patients with Hodgkin Lymphoma (HL) who relapse after conventional therapies. Panobinostat is an orally available pan deacetylase inhibitor with evidence of activity in myeloid malignancies and cutaneous T cell lymphoma. Thirteen HL patients were treated with escalating doses of this novel agent in a phase IA/II multicentre study. A computed tomography partial response was achieved in 5/13(38%), and a metabolic response by 18F-fluoro-2-deoxy-d- glucose positron emission tomography scanning in 7/12 (58%) evaluable patients. This report describes the preliminary evidence of anti-tumour activity seen in the early phase of this study, which recently closed to accrual.

Original languageEnglish (US)
Pages (from-to)97-101
Number of pages5
JournalBritish Journal of Haematology
Volume147
Issue number1
DOIs
StatePublished - Oct 2009

Keywords

  • HDAC inhibitor
  • Hodgkin lymphoma
  • LBH589
  • Panobinostat

ASJC Scopus subject areas

  • Hematology

Fingerprint Dive into the research topics of 'Preliminary evidence of disease response to the pan deacetylase inhibitor panobinostat (LBH589) in refractory Hodgkin Lymphoma'. Together they form a unique fingerprint.

Cite this